Accessibility Menu
NRx Pharmaceuticals Stock Quote

NRx Pharmaceuticals (NASDAQ: NRXP)

$3.15
(-1.9%)
-0.06
Price as of October 22, 2025, 4:00 p.m. ET

KEY DATA POINTS

Current Price
$3.15
Daily Change
(-1.9%) $0.06
Day's Range
$3.05 - $3.26
Previous Close
$3.15
Open
$3.19
Beta
0.91
Volume
1,312
Average Volume
424,223
Market Cap
74.9M
Market Cap / Employee
$3.15M
52wk Range
$1.12 - $6.01
Revenue
-
Gross Margin
-
Dividend Yield
N/A
EPS
-$2.24
CAPs Rating
-
Industry
Pharmaceuticals

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

NRx Pharmaceuticals Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
NRXP+162.5%-97.08%-50.65%-97%
S&P+14.5%+93.32%+14.09%+154%

NRx Pharmaceuticals Company Info

NRX Pharmaceuticals, Inc. is a clinical-stage small molecule pharmaceutical company. It engages in developing of novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded on September 18, 2017 and is headquartered in Wilmington, DE.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$0.00M0.0%
Gross Profit$0.00M100.0%
Market Cap$63.58M172.3%
Net Income-$17.58M-122.6%
EBITDA-$3.73M47.1%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$2.91M53.3%
Inventory00.0%

Liabilities

Q2 2025YOY Change
Long Term Debt$0.00M0.0%
Short Term Debt$10.23M19.1%

Ratios

Q2 2025YOY Change
Return On Assets-669.06%-471.1%
Return On Invested Capital-64.23%27.3%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$4.03M-14.9%
Operating Free Cash Flow-$4.03M-14.9%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book-0.99-1.33-1.29-2.2240.18%
Price to Tangible Book Value-0.99-1.33-1.29-2.2240.18%
Enterprise Value to EBITDA-7.80-8.53-9.74-17.64284.21%
Total Debt$6.67M$6.58M$8.40M$10.23M19.06%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.